Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise
Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems
Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business
Expected to immediately improve path to profitability
ESTERO, FL / ACCESS Newswire / August 10, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that, the Company has completed its previously announced acquisition (the "Acquisition") of Dura Driver Control Systems ("DCS"), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire's ability to deliver increased revenues, durable earnings and cash flow, driven by a new portfolio of product offerings in the large and growing markets for vehicle and mobility control systems.
Pursuant to the terms of the SPA, Aspire has acquired 100% of the issued and outstanding shares of DCS, and DCS has become a wholly owned subsidiary of the Company. Aspire purchased these shares for approximately $30.0 million in cash.
Aspire also announced that, in connection with the Acquisition of DCS, it entered into a $22.5 million senior secured revolving credit facility (the "New Revolving Facility"). Aspire intends to use the borrowings under the New Revolving Facility and cash on hand, to fund the consideration payable for the Acquisition.
DCS CEO Hans Vorstenbosch will continue as CEO of Aspire's DCS subsidiary with the existing DCS management team under the leadership of Gregory J. Corona, the Chairman of Lakewood & Company.
"Closing the DCS acquisition is a cash-flow-positive milestone that structurally enhances Aspire's valuation," said Kraig Higginson, CEO and Chairperson of the Aspire's Board. "Absorbing DCS's FY2025 financial footprint-exceeding $200 million in revenue and $22.3 million in Adjusted EBITDA1 in 2025-immediately elevates us to enterprise scale. This transaction captures immediate, high-volume revenue streams to strengthen our capital flexibility and drive long-term shareholder value."
Key Strategic & Operational Pillars
Strong Financial Profile: For the six months ended June 30, 2026 (unaudited) and twelve months ended December 31, 2025 (audited), DCS generated (a) revenue of approximately $103.9 million and $209.5 million, respectively, (b) Adjusted EBITDA1 of approximately $10.5 million and $22.3 million, respectively.
Global Manufacturing Scale: Operates 11 global manufacturing facilities strategically located across North America, Europe, and Asia.
Blue Chip Customer Base Diversified portfolio of more than 50 customers, highlighted by an average relationship longevity of 28 years with its top 10 OEM clients, supporting more than 150 vehicle platforms and 250 high-volume, global vehicle models.
Extensive Intellectual Property: DCS maintains a proprietary portfolio of over 275 distinct parts and more than 310 patents.
Seasoned Management: The existing DCS leadership team will be bolstered by automotive operating and investment professionals from Lakewood & Company, bringing more than 200 years of collective automotive industry, OEM, tier-one supplier, and industrial sector expertise.
1Non-GAAP Financial Measure Notice: DCS defines Adjusted EBITDA as earnings before interest expense, income tax, depreciation, and amortization, inclusive of specifically identified adjustments. The Company believes Adjusted EBITDA provides useful supplemental information to investors regarding DCS's operational and financial performance. Adjusted EBITDA as presented herein may not be comparable to similarly titled measures reported by other companies.
Advisor
RBW Capital Partners LLC is acting as exclusive financial advisor to the Company in connection with the acquisition. Any securities or brokerage services are offered through Dawson James Securities, Inc.
About Dura Driver Control Systems
DCS is a leading designer and manufacturer of highly engineered automotive and industrial systems that facilitate electronic driver control and support migration toward vehicle electrification, safety, lightweighting, and sustainability. DCS maintains a strong powertrain agnostic product portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific to the proposed acquisition of DCS include, without limitation: the risk that due diligence, including the audit of DCS's financial statements under U.S. GAAP, may reveal information that adversely affects the terms or viability of the transaction; risks related to DCS's business, including its dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential liabilities associated with DCS's operations and intellectual property, the ability to successfully integrate DCS's operations following closing, and the risk that anticipated financial benefits from the acquisition may not be realized, including the risk that the business operations and strategies of DCS and Aspire may diverge. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aspire-biopharma-completes-acquisition-of-dura-driver-control-systems-1205431
